Endoprothèses au sirolimus : données des études RAVEL et SIRIUSBLANCHARD, D; BENSOUDA, C; DANCHIN, N et al.Annales de cardiologie et d'angéiologie (Paris). 2004, Vol 53, pp 9-12, issn 0003-3928, 4 p., SUP1Article

Rapid Inactivation of Proteins by Rapamycin-Induced Rerouting to MitochondriaROBINSON, Margaret S; SAHLENDER, Daniela A; FOSTER, Samuel D et al.Developmental cell. 2010, Vol 18, Num 2, pp 324-331, issn 1534-5807, 8 p.Article

Rapamycin : Clinical results and future opportunitiesKAHAN, Barry D; CAMARDO, Joseph S.Transplantation. 2001, Vol 72, Num 7, pp 1181-1193, issn 0041-1337Article

Direct stenting limits sirolimus-eluting stent edge neointimal thickeningGUERIN, Patrice; GOUËFFIC, Yann; HEYMANN, Marie-Francoise et al.Journal of vascular surgery. 2007, Vol 46, Num 2, pp 354-359, issn 0741-5214, 6 p.Article

Rapamycin pre-treatment protects against apoptosisRAVIKUMAR, Brinda; BERGER, Zdenek; VACHER, Coralie et al.Human molecular genetics (Print). 2006, Vol 15, Num 7, pp 1209-1216, issn 0964-6906, 8 p.Article

A selective small molecule c-MET inhibitor, PHA665752, cooperates with rapamycinMA, Patrick C; SCHAEFER, Erik; CHRISTENSEN, James G et al.Clinical cancer research. 2005, Vol 11, Num 6, pp 2312-2319, issn 1078-0432, 8 p.Article

Rapamycin alleviates toxicity of different aggregate-prone proteinsBERGER, Zdenek; RAVIKUMAR, Brinda; RUBINSZTEIN, David C et al.Human molecular genetics (Print). 2006, Vol 15, Num 3, pp 433-442, issn 0964-6906, 10 p.Article

Sphingosine-1-phosphate-induced smooth muscle cell migration involves the mammalian target of rapamycinTANSKI, William J; NICHOLL, Suzanne M; KIM, Dong et al.Journal of vascular surgery. 2005, Vol 41, Num 1, pp 91-98, issn 0741-5214, 8 p.Article

A limited sampling strategy for estimating sirolimus area-under-the-concentration curveKAPLAN, B; MEIER-KRIESCHE, H.-U; NAPOLI, K et al.Clinical chemistry (Baltimore, Md.). 1997, Vol 43, Num 3, pp 539-540, issn 0009-9147Article

Immunosuppressive drug rapamycin restores sporulation competence in industrial yeastsNAKAZAWA, Nobushige; NIIJIMA, Seiko; TANAKA, Yukari et al.Journal of bioscience and bioengineering. 2012, Vol 113, Num 4, pp 491-495, issn 1389-1723, 5 p.Article

Stent coronaire à libération de sirolimus : les leçons de l'expérience de RotterdamLEMOS, P. A; MCFADDEN, E. P; ONG, A. T. L et al.Annales de cardiologie et d'angéiologie (Paris). 2004, Vol 53, pp 32-35, issn 0003-3928, 4 p., SUP1Article

Functional interaction of mammalian target of rapamycin complexes in regulating mammalian cell size and cell cycleROSNER, Margit; FUCHS, Christiane; SIEGEL, Nicol et al.Human molecular genetics (Print). 2009, Vol 18, Num 17, pp 3298-3310, issn 0964-6906, 13 p.Article

Coronary uptake of gallium-67 citrate after implantation of sirolimus-eluting stentKRITHARIDES, Leonard; YIANNIKAS, John; BRIEGER, David et al.Circulation (New York, N.Y.). 2004, Vol 109, Num 17, issn 0009-7322, p. 2156Article

Pharmacokinetics and metabolism of sirolimusGALLANT-HAIDNER, H. L; TREPANIER, D. J; FREITAG, D. G et al.Therapeutic drug monitoring. 2000, Vol 22, Num 1, pp 31-35, issn 0163-4356Article

Chemical genetics screen for enhancers of rapamycin identifies a specific inhibitor of an SCF family E3 ubiquitin ligaseAGHAJAN, Mariam; NAO JONAI; DAMOISEAUX, Robert et al.Nature biotechnology (Print). 2010, Vol 28, Num 7, pp 738-742, issn 1087-0156, 5 p.Article

Cytoplasmic and nuclear distribution of the protein complexes mTORC1 and mTORC2 : rapamycin triggers dephosphorylation and delocalization of the mTORC2 components rictor and sin1ROSNER, Margit; HENGSTSCHLÄGER, Markus.Human molecular genetics (Print). 2008, Vol 17, Num 19, pp 2934-2948, issn 0964-6906, 15 p.Article

Contribution of stent underexpansion to recurrence after sirolimus-eluting stent implantation for in-stent restenosisFUJII, Kenichi; MINTZ, Gary S; REYES, Arlene et al.Circulation (New York, N.Y.). 2004, Vol 109, Num 9, pp 1085-1088, issn 0009-7322, 4 p.Article

Mammalian target of rapamycinMERIC-BERNSTAM, Funda; MILLS, Gordon B.Seminars in oncology. 2004, Vol 31, Num 6, pp 10-17, issn 0093-7754, 8 p., SUP16Article

Sirolimus-associated diffuse alveolar hemorrhageVLAHAKIS, Nicholas E; RICKMAN, Otis B; MORGENTHALER, Timothy et al.Mayo Clinic proceedings. 2004, Vol 79, Num 4, pp 541-545, issn 0025-6196, 5 p.Article

Le registre Siro-ISR : traitement de la resténose intra-stent par le stent au sirolimus dans le monde réelBARRAGAN, P; ROQUEBERT, P.-O; COMMEAU, P et al.Annales de cardiologie et d'angéiologie (Paris). 2004, Vol 53, pp 45-46, issn 0003-3928, 2 p., SUP1Article

Mammalian target of rapamycin inhibitionDUTCHER, Janice P.Clinical cancer research. 2004, Vol 10, Num 18, pp 6382s-6387s, issn 1078-0432, 2Conference Paper

Control of ribosome biosynthesis by the target of rapamycin (TOR)CHI KWAN TSANG; ZHENG, X. F.Recent research developments in molecular & cellular biology (Vol. 5 (2004)). Recent research developments in molecular & cellular biology. 2004, pp 135-147, isbn 81-7736-213-5, 13 p.Book Chapter

Les rapamycines, nouveaux immunosuppresseurs: des mécanismes d'action aux applications cliniques = Rapamycines, new immunodepressors: from mode of action to clinical applicationsMORELON, Emmanuel.MT. Médecine thérapeutique. 2001, Vol 7, Num 2, pp 152-156, issn 1264-6520Article

Rapamune : a novel macrolide immunosuppressant for transplantationLATTA, D.Human & experimental toxicology. 2000, Vol 19, Num 4, issn 0960-3271, p. 229Conference Paper

Activation of mammalian target of rapamycin in cytomegalic neurons of human cortical dysplasiaLJUNGBERG, M. Cecilia; BHATTACHARJEE, Meenakshi B; YAOJUAN LU et al.Annals of neurology. 2006, Vol 60, Num 4, pp 420-429, issn 0364-5134, 10 p.Article